According to the Health Yuan announcement, Lizhu Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the approval and issuance of the “Drug Clinical Trial Approval Notice” for NS-041 tablets to be added to the “treatment of depression”.

According to the Health Yuan announcement, Lizhu Pharmaceutical Co., Ltd., a holding subsidiary of the company, has received the approval and issuance of the “Drug Clinical Trial Approval Notice” for NS-041 tablets to be added to the “treatment of depression”.